BANGALORE, India and DELAWARE CITY, Del. and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ Bugworks Research Inc., a clinical-stage biopharmaceutical company, is set to present its latest research findings on the novel bacterial topoisomerase inhibitor, BWC0977 at the upcoming 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark. The eight posters highlight data from the microbiological and efficacy studies of the clinical candidate, BWC0977 that exhibits broad-spectrum activity against a globally, diverse panel of Gram-positive, Gram-negative and biothreat pathogens. Additionally, data from a range of studies, including in vitro biochemical assays, in vitro resistance frequency studies, minimum inhibitory concentration (MIC90) data against multi-drug resistant clinical isolates from around the world, and in vivo efficacy data in mice and rat models of infection will be presented. These studies were conducted in collaboration wi
BANGALORE, India and DELAWARE CITY, Del. and ADELAIDE, Australia, April 17, 2023 /PRNewswire/ Bugworks Research Inc., a clinical-stage biopharmaceutical.